The forum of biomedical industrial exchange between Taiwan and Singapore |
Healthcare Industry Development Association across the Strait (HIDAS) has been focused on the collaboration and promotion of the healthcare industry between Taiwan and other countries in Asia. HIDAS is pleased to present an opportunity for biomedical industries between Taiwan and Singapore to discuss and exchange any possibilities of collaboration.
Singapore has been enhancing its existing biomedical R&D infrastructure, integrate multi-disciplinary research and translate basic science into tangible outcomes. The most successful investments of Singapore biomedical development are supporting the country’s biomedical initiative, such as Biopolis that comprises hospitals, medical institutes, medical schools, public research institutes, and corporate laboratories. The development of biomedical industries in Taiwan is also greatly supported by the government, and the sum of business turnover for biopharmaceutical industry in 2014 was around 9.3 billion US dollars. The needs of biomedical products are increasing, and many biomedical companies in Taiwan are seeking collaboration in order to advance the technology, manufacture the products that match the clinical needs, and expand the market.
The experience of successful public-private biomedical collaboration in Singapore is impressive, and the future planning of biomedical industry in Taiwan tends to expand internationally. This forum provides a great opportunity for biomedical industries in Taiwan and Singapore to understand each other’s current biomedical situation, and provides connections to promote and stimulate possibilities of further collaboration.
中華海峽兩岸醫療暨健康產業發展協會(簡稱:醫健會)以推動台灣和亞太地區國家間的生技產業交流和合作為目標。此次醫健會舉辦新加坡台灣生醫產業研討交流論壇,希望提供新加坡和台灣生醫產業業者有互相交流並討論未來合作的可能性。
新加坡致力於生醫研發基礎設施、整合多項生醫領域研究以及著重轉譯醫學,最成功的發展為支持打造國家生醫製造群聚,例如啟奧生醫園區(Biopolis)即是結合醫院、醫學院、政府研究中心和生醫產業實驗中心的生醫重鎮。台灣的生醫產業也在政府積極推廣並支持下,2014年生物醫藥產業營業額為美金93億元。在生醫產品需求增加的情形下,台灣生醫業者開始尋求合作以利技術精進、製造符合臨床需求之產品以及開拓市場。
新加坡成功的整合政府-私人企業資源使生醫產業蓬勃發展,而台灣生醫產業則趨向國際化的合作。醫健會舉辦此次論壇將串連新加坡和台灣兩方產、官、學之能量,透過政府對生醫產業的展望以及新加坡醫藥食品的法規概述為主軸,提供新加坡和台灣的生醫產業業者有更加了解彼此生醫發展現況的機會,以及促進未來兩方合作的可能性。
Singapore has been enhancing its existing biomedical R&D infrastructure, integrate multi-disciplinary research and translate basic science into tangible outcomes. The most successful investments of Singapore biomedical development are supporting the country’s biomedical initiative, such as Biopolis that comprises hospitals, medical institutes, medical schools, public research institutes, and corporate laboratories. The development of biomedical industries in Taiwan is also greatly supported by the government, and the sum of business turnover for biopharmaceutical industry in 2014 was around 9.3 billion US dollars. The needs of biomedical products are increasing, and many biomedical companies in Taiwan are seeking collaboration in order to advance the technology, manufacture the products that match the clinical needs, and expand the market.
The experience of successful public-private biomedical collaboration in Singapore is impressive, and the future planning of biomedical industry in Taiwan tends to expand internationally. This forum provides a great opportunity for biomedical industries in Taiwan and Singapore to understand each other’s current biomedical situation, and provides connections to promote and stimulate possibilities of further collaboration.
中華海峽兩岸醫療暨健康產業發展協會(簡稱:醫健會)以推動台灣和亞太地區國家間的生技產業交流和合作為目標。此次醫健會舉辦新加坡台灣生醫產業研討交流論壇,希望提供新加坡和台灣生醫產業業者有互相交流並討論未來合作的可能性。
新加坡致力於生醫研發基礎設施、整合多項生醫領域研究以及著重轉譯醫學,最成功的發展為支持打造國家生醫製造群聚,例如啟奧生醫園區(Biopolis)即是結合醫院、醫學院、政府研究中心和生醫產業實驗中心的生醫重鎮。台灣的生醫產業也在政府積極推廣並支持下,2014年生物醫藥產業營業額為美金93億元。在生醫產品需求增加的情形下,台灣生醫業者開始尋求合作以利技術精進、製造符合臨床需求之產品以及開拓市場。
新加坡成功的整合政府-私人企業資源使生醫產業蓬勃發展,而台灣生醫產業則趨向國際化的合作。醫健會舉辦此次論壇將串連新加坡和台灣兩方產、官、學之能量,透過政府對生醫產業的展望以及新加坡醫藥食品的法規概述為主軸,提供新加坡和台灣的生醫產業業者有更加了解彼此生醫發展現況的機會,以及促進未來兩方合作的可能性。
Date: August 31, 2016 (Wednesday)
Time: 10:30 – 12:00
Location: Marina Bay Sands Conference Room, Angsana 3B,
Organizer: Healthcare Industry Development Association across the Strait (Hidas)
Partners: Health Essence of Asia
Time: 10:30 – 12:00
Location: Marina Bay Sands Conference Room, Angsana 3B,
Organizer: Healthcare Industry Development Association across the Strait (Hidas)
Partners: Health Essence of Asia
Time |
Session |
1035-1045 |
Opening Address Visitant: Dr. Kuo Tung Liao, Founder and current president of HIDAS, Taiwan Legislator. Representative of Taipei Representative Office in Singapore (To be invited) Ministry of Health, Singapore (To be invited) |
1045-1100 |
Topic: Development and current situation of biomedical industries in Taiwan (I) Speaker: Prof. Hsu-Wei Fang, Vice president of HIDAS |
1100-1115 |
Topic: Development and current situation of biomedical industries in Taiwan (II) Speaker: Ching-Lung Hu, Senior Manager of Biotechnology and Pharmaceutical Industries Promotion Office, MOEA, Taiwan |
1115-1130 |
Topic: The regulation of drug, medical device, and food in Singapore Speaker: Ministry of Health, Singapore (To be invited) Agri-Food & Veterinary Authority of Singapore (To be invited) |
1130-1200 |
Panel Discussion: The prospective and policy of biomedical industry in Singapore Chairman: Perry Chyau, Vice president of HIDAS Discussant: Peggy P.J. Chang, Chief Representative Officer of Taiwan Trade Center in Singapore (To be invited) Singapore Economic Development Board (To be invited) |
Website of HIDAS: www.hidas.org.tw
Contact: Prof. Hsu-Wei Fang, [email protected] / [email protected]
Contact: Prof. Hsu-Wei Fang, [email protected] / [email protected]